Clinical Trial Goal
To find out:
- The highest dose of CTX-712 that's safe to give
- If CTX-712 is safe and works well to treat AML or high-risk MDS that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years old or older
- Have one of the following that has relapsed or is refractory:
- AML
- MDS that doctors consider to be high-risk
- Do not have acute promyelocytic leukemia
- Do not have lymphoma in your brain or spinal cord
- Have not been treated with CAR T-cell therapy
- Have not had allogeneic (cells from a donor) blood or marrow transplant in the last 6 months
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
CTX-712 is a pan-CLK inhibitor that targets SLK kinase in certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
- CTX-712 – A pill that you take by mouth 1 time each week
You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to 2 years.
The Food and Drug Administration (FDA) has not yet approved CTX-712.
Contacts
Laurie F Graham, RN, MSN, (609) 608-2152, lgraham@theradex.com
Haris Durutlic, (781) 560-4419, hdurutlic.chordia@gmail.com
Locations
Sponsors
collaborator: Theradex, lead: Chordia Therapeutics, Inc.
